157160-99-1

Basic information

• Product Name: Benzoic acid, 4-chloro-3-nitro-, 1,1-dimethylethyl ester
• CAS NO: 157160-99-1
• Molecular Formula: C11H12ClNO4
• Molecular Weight: 257.674
• Mol File: 157160-99-1.mol
• Article Data: 12

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 4-chloro-3-nitro-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 4-chloro-3-nitro-, 1,1-dimethylethyl ester(157160-99-1)
• EPA Substance Registry System: Benzoic acid, 4-chloro-3-nitro-, 1,1-dimethylethyl ester(157160-99-1)

Safety Data

• Hazardous Substances Data: 157160-99-1(Hazardous Substances Data)

Upstream product

• 865-47-4 potassium tert-butylate 
• 38818-50-7 4-chloro-3-nitro-benzoyl chloride 
• 115-11-7 isobutene 
• 96-99-1 4-chloro-3-nitrobenzoate 
• 75-65-0 tert-butyl alcohol 
• 36805-97-7 N,N-dimethylformamide di-tert-butyl acetal 

Downstream Products

• 253192-24-4 4-(4-tert-butoxycarbonyl-2-nitrophenylamino)piperidine-1-carboxylic acid tert-butyl ester 
• 185424-58-2 Dimethyl (4-carboxy-2-nitrophenyl)malonate 
• 440344-65-0 C₁₆H₁₆N₄O₄ 
• 234082-22-5 3-nitro-4-{4-(pyrimidin-2-yl)piperazin-1-yl}benzoic acid 
• 312921-86-1 C₁₈H₁₉N₃O₄ 
• 1613475-24-3 tert-butyl 3-amino-4-(4-methylpiperazin-1-yl)benzoate 
• 1613475-25-4 tert-butyl 3-(benzyloxycarbonylamino)-4-(4-methylpiperazin-1-yl)benzoate 
• 1613475-26-5 3-(benzyloxycarbonylamino)-4-(4-methylpiperazin-1-yl)-benzoic acid 
• 1613475-22-1 benzyl N-[5-carbamoyl-2-(4-methylpiperazin-1-yl)phenyl]carbamate 

Relevant articles and documents

COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS

The present disclosure provides, inter alia, a compound having the structure (1). Also provided are compositions containing a pharmaceutically acceptable carrier and one or more compounds according to the present disclosure. Further provided are methods f

Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models

Ferrostatin-1 (Fer-1) inhibits ferroptosis, a form of regulated, oxidative, nonapoptotic cell death. We found that Fer-1 inhibited cell death in cellular models of Huntington's disease (HD), periventricular leukomalacia (PVL), and kidney dysfunction; Fer-1 inhibited lipid peroxidation, but not mitochondrial reactive oxygen species formation or lysosomal membrane permeability. We developed a mechanistic model to explain the activity of Fer-1, which guided the development of ferrostatins with improved properties. These studies suggest numerous therapeutic uses for ferrostatins, and that lipid peroxidation mediates diverse disease phenotypes.

THERAPEUTIC AGENT FOR CEREBRAL INFARCTION

The invention provides a therapeutic drug for ischemic stroke. The therapeutic drug has the formula (I) wherein each symbol is as defined herein, or a pharmacologically acceptable salt thereof, or a solvate thereof, as an active ingredient.